Edition:
United States

Profile: Nevro Corp (NVRO.N)

NVRO.N on New York Stock Exchange

61.66USD
19 Jul 2019
Change (% chg)

$-1.60 (-2.53%)
Prev Close
$63.26
Open
$63.25
Day's High
$64.17
Day's Low
$61.62
Volume
48,466
Avg. Vol
107,862
52-wk High
$68.79
52-wk Low
$34.82

Nevro Corp., incorporated on October 4, 2006, is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Company's HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain. HF10 therapy enables patients to achieve sustained pain relief without paresthesia, thus enabling its patients to avoid the uncomfortable shocking or jolting sensations commonly associated with paresthesia. HF10 therapy relies on consistent anatomical lead placement. As of December 31, 2016, the Company was engaged in investigating the use of HF10 therapy to address additional indications, such as chronic upper limb and neck pain, painful neuropathies and non-surgical refractory back pain.

The Senza system is approved to create electrical impulses from 2 hertz (Hz) to 10,000 Hz, including its HF10 therapy, which allows for pain relief without paresthesia. HF10 therapy delivers waveforms at 10,000 Hz pulse rate with a statistically driven and clinically verified programming algorithm. Senza consists of leads, a trial stimulator, an implantable pulse generator (IPG), surgical tools, a clinician laptop programmer, a patient remote control and a mobile charger. The IPG contains a rechargeable battery and electronics that deliver electrical pulses to the lead. The percutaneous leads vary in length and are thin, insulated medical wires in a cylindrical, flexible and steerable shape that conduct electrical pulses from the IPG to near the spinal cord. The Surpass surgical leads are similar to its percutaneous leads but in a larger paddle-shaped format that provides a larger surface area that broaden exposure of the lead along the vertebrae.

The trial stimulator contains electronics that deliver electrical pulses to the lead. Surgical tools include percutaneous insertion needles that are used to introduce the lead into the epidural space, a range of stylets that give physicians the ability to steer and deliver the lead to the desired location, anchors to secure the leads and tunneling tools that provide access from the lead insertion site to the location of the IPG. The clinician laptop programmer contains software that allows the customized per patient programming of the IPG. The patient remote control is a handheld device that allows patients to turn their stimulation on and off and change programs uploaded to their IPG. The charger recharges the IPG from outside the body.

The Company competes with Medtronic plc, Boston Scientific Corporation, Abbott Laboratories, Stimwave, Nuvectra and Saluda.

Company Address

Nevro Corp

1800 Bridge Pkwy
REDWOOD CITY   CA   94065-1164
P: +1650.2510005
F: +1302.6555049

Company Web Links